Wideblue design saves money during development of new drugs

01 July 2010

Biopta have published a paper describing an application of their unique PM-1 perfusion myograph instrument, which was designed and manufactured by Wideblue.

The PM-1 allows new drug candidates to be screened for adverse reactions at an early stage in drug development, resulting in better prediction of the safest and most effective drugs.